Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368415 | 0.91 | CSNK1E (0.49) | CSNK1EFAAH | |
| SCHEMBL4044169 | 0.91 | ALDH1A1 (0.52) | CSNK1ENPC1RAB9A | |
| SCHEMBL14368388 | 0.90 | CSNK1E (0.53) | CSNK1E | |
| SCHEMBL13964367 | 0.90 | CSNK1E (0.56) | CSNK1EMAPTNPC1RAB9AFAAH | |
| SCHEMBL13963918 | 0.89 | CSNK1E (0.52) | CSNK1ENPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL14368412 | 0.89 | CSNK1E (0.51) | CSNK1EMAPTNPC1RAB9ATAS1R3 | |
| SCHEMBL14368531 | 0.88 | CSNK1E (0.50) | CSNK1E | |
| SCHEMBL4042496 | 0.88 | CSNK1E (0.45) | CSNK1ENPC1RAB9AFAAH | |
| SCHEMBL14368390 | 0.88 | CSNK1E (0.52) | CSNK1EFAAHTRPV1 | |
| SCHEMBL14368450 | 0.88 | CSNK1E (0.47) | CSNK1ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CSNK1E 136/4885MAPT 751/4885NPC1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.